{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:42:11Z","timestamp":1759585331263,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014039","name":"US Department of Defense Prostate Cancer Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.eururo.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T04:05:31Z","timestamp":1623989131000},"page":"e83-e84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi\u2019s Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate"],"prefix":"10.1016","volume":"80","author":[{"given":"Scott","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosina T.","family":"Lis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-1853","authenticated-orcid":false,"given":"Adam G.","family":"Sowalsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.06.002_bib0005","doi-asserted-by":"crossref","unstructured":"Wilkinson S, Ye H, Karzai F, et al. Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.009.","DOI":"10.1016\/j.eururo.2021.03.009"},{"key":"10.1016\/j.eururo.2021.06.002_bib0010","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","article-title":"Outcomes post neoadjuvant intense hormone therapy and surgery for patients with high-risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials","volume":"205","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.06.002_bib0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41467-020-14657-7","article-title":"A case report of multiple primary prostate tumors with differential drug sensitivity","volume":"11","author":"Wilkinson","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2021.06.002_bib0020","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.06.002_bib0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000001702","article-title":"Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer","volume":"206","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.06.002_bib0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","article-title":"A prostate cancer \u201cnimbosus\u201d: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies","volume":"72","author":"Chua","year":"2017","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382101808X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382101808X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:10:18Z","timestamp":1759583418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382101808X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S030228382101808X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.06.002","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, and Rodolfo Montironi\u2019s Letter to the Editor re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.06.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}